Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707475 | 0.95 | PDE4A (0.47) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3136289 | 0.91 | CTSL (0.49) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3132190 | 0.88 | CTSL (0.47) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3138215 | 0.85 | PDE4A (0.51) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3130747 | 0.82 | CTSL (0.58) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3142270 | 0.81 | CTSL (0.55) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3137550 | 0.81 | CCNE1 (0.52) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3137222 | 0.80 | CTSL (0.59) | CTSLCTSBTLR7CTSS | |
| SCHEMBL3133681 | 0.80 | PDE4A (0.63) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3141308 | 0.80 | CTSL (0.49) | YTHDC1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | claimed |
| CN-100439370-C | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-12-03 | — | — | CN | claimed |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2008-05-22 | — | — | US | claimed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | claimed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | claimed |
| CN-1501927-A | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | 记忆药物公司 | 2004-06-02 | — | — | CN | claimed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | claimed |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| EP-1529049-B1 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | disclosed |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2008-05-22 | — | — | US | disclosed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| CN-1688580-A | 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | disclosed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | disclosed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | YTHDC1 3986/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | YTHDC1 3986/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | YTHDC1 3888/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | YTHDC1 3986/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | YTHDC1 3888/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | YTHDC1 3986/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | YTHDC1 3986/4885PDE4A 1/4885PDE4B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.